Sumatriptan
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Sumatriptan
Description :
Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research[1][2][3][4].Product Name Alternative :
GR 43175 free baseUNSPSC :
12352005Hazard Statement :
H361, H412Target :
5-HT ReceptorType :
Reference compoundRelated Pathways :
GPCR/G Protein; Neuronal SignalingApplications :
Neuroscience-NeuromodulationField of Research :
Neurological DiseaseAssay Protocol :
https://www.medchemexpress.com/sumatriptan.htmlPurity :
99.96Solubility :
DMSO : 50 mg/mL (ultrasonic)Smiles :
O=S(CC1=CC2=C(NC=C2CCN(C)C)C=C1)(NC)=OMolecular Formula :
C14H21N3O2SMolecular Weight :
295.41Precautions :
H361, H412References & Citations :
[1]K L Dechant, et al. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992 May;43 (5) :776-98.|[2]S J Peroutka, et al. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989 Apr 12;163 (1) :133-6. |[3]Razzaque Z, et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol. 1999 Jan;47 (1) :75-82.|[4]Bates EA, et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 2010 Feb;30 (2) :170-8.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
5-HT1 Receptor; mLAG-3Citation 01 :
ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|J Headache Pain. 2024 Oct 30;25 (1) :187.|Mol Pharmacol. 2023 Nov;104 (5) :230-238.|Personalized Medicine Universe. 2019 May.CAS Number :
[103628-46-2]

